Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RWS progresses strategy as price challenges persist

(Sharecast News) - RWS Holdings reported continued progress on its medium-term strategy in an update on Tuesday, having returned to organic constant currency growth in the second half of its 2024 financial year. The AIM-traded firm, which was holding its annual general meeting, said client retention levels remained high and client satisfaction had improved, while it secured significant new business.

Investments in growth initiatives and efficiency measures had enabled RWS to pivot successfully towards AI-led and specialist solutions, supporting a more resilient performance.

The company said it had seen further organic constant currency growth in the first quarter of its 2025 financial year, driven by strong volumes in its services divisions.

However, pricing and mix challenges persisted.

The board said the language and content technology division and TrainAI, its data training business, had maintained positive momentum, reinforcing the shift towards the company's identified growth areas.

RWS said its cost control programme was progressing as planned, with the majority of benefits expected to materialise in the second half of the year.

The company added that it was continuing to seek efficiency improvements through process optimisation and increased use of technology.

"In line with our previous guidance, we expect to deliver modest organic constant currency revenue growth in 2025, with growth in volumes anticipated to more than offset ongoing price pressure," said chairman Julie Southern.

At 1005 GMT, shares in RWS Holdings were up 6.85% at 149.8p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.